Fluxion Biosciences, Inc. announced today that a lawsuit alleging patent
infringement had been filed against it in the US District Court of
Northern California by Cellectricon AB, its competitor in the field of
automated ion channel screening systems for drug discovery. Cellectricon
has asserted U.S. Patents Nos. 7,390,650, 7,470,518, and 7,563,614 in
the litigation, as well as U.S. Patent No. 5,376,252, which is owned by
Gyros and licensed to Cellectricon. Fluxion believes that the lawsuit is
without merit and that Fluxion’s innovative IonFlux™ automated patch
clamp system does not infringe the asserted patents. Fluxion intends to
defend this lawsuit vigorously.
“Fluxion has invested considerable time and resources to
develop its own intellectual property position for cell-based screening
systems, and we respect the intellectual property rights of others.
Cellectricon’s claim of patent infringement is a baseless attempt to
block Fluxion’s penetration and growth in the ion channel screening
market.”
Jeff Jensen, Chief Executive Officer of Fluxion, said in response to the
lawsuit: "Fluxion has invested considerable time and resources to
develop its own intellectual property position for cell-based screening
systems, and we respect the intellectual property rights of others.
Cellectricon’s claim of patent infringement is a baseless attempt to
block Fluxion’s penetration and growth in the ion channel screening
market.”
SOURCE Fluxion Biosciences
Fluxion Biosciences reports first study results from early stage NSCLC patients